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Abstract
Synthetic glucocorticoids (GC) are used as a clinical therapeutic to stimulate lung
development in fetuses that present the risk of preterm delivery. Previous studies have shown
that a prenatal exposure to Dexamethasone (DEX) causes a disturbance in normal GC mediation
of neuritic outgrowth, cell signaling, and serotonergic systems. Our hypothesis is that a prenatal
exposure to DEX during the third trimester of pregnancy alters 5HT1A receptor function.
Pregnant dams were injected daily with 150µg/ml/kg of DEX from gestation day 14 through 19.
Control dams were treated with and equal volume of saline. Swim stress followed by elevated
plus maze testing was conducted on male rats an hour and a half prior to being sacrificed to
induce postnatal acute stress. The non-stressed group was also tested and allowed to return to
baseline before sacrifice. Hippocampi were analyzed using a radioligand-receptor binding assay
and GTPγS35 incorporation (3H-MPPF antagonist and 8-OH-DPAT agonist, respectively). A
significant increase in Kd was found in non-stressed DEX-exposed animals compared to nonstressed controls (p<0.05). Moreover, Kd decreased significantly in the DEX-exposed stressed
rats when compared with their non-stressed cohorts (p<0.05). When the Kd of all Dex-treated
animals (DEXtot) animals was compared to the Kd of all control animals (Controltot) animals, the
Kd of the DEXtot group was significantly increased. In contrast, the Kd measured in all animals
exposed to stress (stressedtot) was significantly decreased in comparison to all non-stressed
animals (non-stressedtot). The Bmax increased significantly in response to prenatal DEX when
DEXtot were compared to Controltot (p<0.05). However, the Bmax significantly decreased in
response to postnatal stress when combined stressed groups (stressedtot) were compared
combined non-stressed groups (non-stressedtot) (p<0.05). In addition, a postnatal acute stressor
caused a significant increase in the Emax for both the prenatal DEX treated and control animals as
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compared to their unstressed littermates (p<0.05). Based on these results it is possible to say that
a prenatal exposure to Dexamethasone significantly increases the receptor Kd in the adult male
rats under resting conditions. This loss of affinity may initiate a compensatory action which
would include an increase in receptor density. However, under periods of stress, both control and
prenatally DEX treated animals showed an increase in receptor affinity. The increased Emax
observed in stressed animals could be due to a shift in 5HT1A receptor population from an
inactive to active state. Our results suggest that there are differential changes in 5HT1A receptor
density and activity in the hippocampus of the male rat in response to a prenatal exposure to
DEX as well as an acute stressor in adulthood.

3
Introduction
Throughout our lives we face stress in all different forms. These stressors can be
physical, chemical, and even emotional. Regardless of the stressor, they elicit a similar response
from the sympathetic nervous system and the hypothalamic-pituitary-adrenal axis (HPA)
(Munck, Guyre, & Holbrook, 1984). This “stress response” allows the body to adapt to challenge
and maintain homeostatic balance which ensures that vital functions such as blood pH and
hormone release will be regulated in response to the body’s ever-changing needs.
Stressors are detected via a sensory system that transmits signals to the hypothalamus,
the major integration center of the brain. Specifically the signals are sent to the parvocellular
neurons of the paraventricular nucleus (PVN), which is the integration site for the stress response
within the hypothalamus (Lopez, Young, Herman, Akil, & Watson, 1998). Activation of the
PVN differentially modulates a number of physiological systems. For example, the immune
system and the inflammatory response are suppressed whereas the production of arginine
vasopressin (AVP) and corticotropin-releasing hormone (CRH) are increased in response to PVN
activation (Munck, Guyre, & Holbrook, 1984) (Lopez, Young, Herman, Akil, & Watson, 1998).
AVP decreases the amount of water lost during renal excretion, while CRH initiates the HPA
axis cascade that ultimately leads to the release of cortisol in human and corticosterone in rats
(Lopez, Young, Herman, Akil, & Watson, 1998). It is this latter component and its ramifications
that will be a central focus for this research.
After the stress signal is received and processed by the hypothalamus, CRH is released.
CRH then acts on the anterior pituitary and promotes the release of adrenocorticotropin hormone
(ACTH). ACTH is a trophic hormone that enters the blood stream and acts on the adrenal gland
which produces the final product of the HPA axis, cortisol (Miller & O'Callaghan, 2002). In rats
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the final product of the HPA axis is corticosterone (CORT) which is very similar in structure to
cortisol, the human stress hormone.
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Figure 1. Structures showing similarities between a. corticosterone, b. cortisol, and c.
Dexamethasone.
Naturally occurring glucocorticoids, such as CORT, are steroid hormones synthesized in
the adrenal cortex and are involved in the regulation of mineral and salt secretion and in
regulation of glucose metabolism via binding of mineralocorticoid (MR) and glucocorticoid
(GR) receptors, respectively. CORT acts on a wide range of organs including several brain
regions, particularly limbic regions such as the hypothalamus and hippocampus (Miller &
O'Callaghan, 2002). The HPA-mediated release of CORT is controlled further through a
negative feedback loop. Negative feedback loops occur when the product of the cycle acts to
inhibit the components involved in producing it. In other words, the end product of HPA axis
activation, CORT, acts directly on the anterior pituitary and hypothalamus to inhibit the
production of CRH and ACTH, respectively. Moreover, CORT acts back on mineralocorticoid
receptors and glucocorticoid receptors in the hippocampus in order to change the central drive on
the HPA axis. The hippocampus is known to be the central “pulse generator” which establishes
the neuroendocrine set point for this system during development. It should be noted that
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neuroendocrine loops are continuously interacting and it has been shown that serotonergic
activity and the release of serotonin, can have inhibitory effects on the HPA axis by inducing
negative regulation of CORT (Gold & Chrousos, 1999).
Both MR and GR receptors are involved in the regulation of the HPA axis feedback.
Activation of these receptors initiates the negative feedback mechanism of the HPA axis. MR
receptors in the brain have ten times higher affinity for glucocorticoids than GR receptors. This
suggests that under basal conditions the cell’s CORT responses are dictated by MR, and only
during times of increased HPA axis activity and increased CORT levels will there be appreciable
levels of GR activation (de Kleot ER, 1998). Although it is well known that GR is involved in
peripheral glucose metabolism and nutrient mobilization, differential activation of MR and GR
are key determinants of transcriptional regulation for genes that regulate glucose metabolism,
mineral retention, memory formation, memory processing in the brain (Lu, Wardell, Burnstein,
Defranco, FULLER, & Gigure, 2006).
GR is expressed in most brain regions and is found almost equally in both neurons and
glial cells (de Kloet, 1991). MR and GR are co-expressed in very specific brain regions, most
importantly the hippocampus, which relates to its involvement in memory formation.
Prolonged increases in CORT levels due to conditions such as HPA axis hyperactivity
have been shown to have negative impacts on memory formation and neuronal potentiation.
However, when the HPA axis activity is up-regulated for only short periods of time, preferential
binding to MR receptors has been observed over GR (McEwen & Saplosky, 1995). During short
periods of high CORT, the enhanced MR activation and low levels of GR activation may have
positive impacts on the potentiation of memory, but when high serum CORT levels are
circulating for an extended period of time, inhibitory effects on these memory processes are
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observed (McEwen & Saplosky, 1995). Therefore, due to the biphasic binding model of CORT
to MR and GR the short term effects of HPA axis up regulation can have positive effects on the
consolidation of memory, while long term effects can have deleterious effects on the same
system (Reul & de Kloet, 1985) (Oitzl & de Kloet, 1992).
HPA axis set points vary during the lifetime of an individual. During development,
specifically during the third trimester, the fetal neuroendocrine system is highly plastic, and any
prolonged elevations or deprivations of hormones or other necessary components during this
time period can have long lasting effects on the individual (Pariante & Lightman, 2008)
(Takahashi, Turner, & Kalin, 1998). Increases in fetal CORT levels rise in response to stressors
imposed on the mother during pregnancy. These stressors can come from mental, physical,
emotional stressors, or even the administration of synthetic glucocorticoids, but all of these
challenges have been shown to induce significant change in both maternal and fetal
corticosterone levels (Douglas, 1975) (Barbazanges, Piazza, Le Moal, & Maccari, 1996) (Ward
& Weisz, 1991).
Of interest to our study is the fact that DEX is a synthetic glucocorticoid administered in
approximately 10% of human pregnancies in the United States (NIH Consensus, 2000). DEX is
administered to mothers that are at risk for preterm deliveries. One of the main reasons for this is
that glucocorticoids have been shown to promote surfactant production in the fetus. This is
critical because without surfactant the surface tension around the alveoli would be too great and
it would lead to alveolar collapse (Kattner, Metze, & Waisse, 1992). However, despite being a
powerful tool in surfactant stimulation, prenatal DEX exposure has unwanted side effects. For
example, DEX administration decreases maternal CORT levels, but increases total levels of
circulating glucocorticoids, as DEX is a glucocorticoid. This increase in glucocorticoid
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concentration in the prenatal environment has been associated with low birth weight offspring
and other neurophysiological disturbances (Shoener, Baig, & Page, 2005) (de Kleot ER, 1998).
These disturbances may be due to the inability of the body’s defense mechanisms to recognize
DEX. For example, adult neuronal cells have a membrane pump, mdr1a P-glycoprotein, in the
blood brain barrier that opposes glucocorticoid transport into the brain and protects maternal
neurons from elevated glucocorticoid levels. However, during the third trimester the fetal bloodbrain barrier is not fully developed and the underdevelopment of the mdr1a P-glycoprotein
defense mechanism during the time of DEX administration allows DEX to interact with the
developing fetal brain (Owen, 2002). In addition, the effects of DEX are more effective
compared to those of CORT because DEX has a longer half-life and a much higher affinity for
GR receptors than does CORT. Thus, it is degraded more slowly and binds more effectively to
GR receptors in comparison to endogenous CORT (Orth & Kovac, 1998) (Rupprecht, Reul, &
Van Steensel, 1993). If DEX binds GR with a higher affinity and disturbs the MR/GR functions
during times when MR should be controlling the CORT response, a dysfunctional
neuroendocrine regulatory loop will be established in the developing fetus (Rupprecht, Reul, &
Van Steensel, 1993). This is underscored by the fact that the DEX/MR receptor ligand complex
is very unstable and this instability leads to weak activation of downstream gene transcription
regulators mediated by MR (Ruel, Gressing, Droste, & al, 2000).
To protect the fetus from the effects of increased corticosterone, the maternal-placental
barrier has proteins to prevent the flow of active CORT to the fetus. For example, the active from
of CORT, corticosterone, can be converted to a biologically inactive form, 11dehydrocorticosterone, by 11-Beta-hydroxysteroid dehydrogenase (11β-HSD) (Yang, 1995).
Two forms of 11β-HSD exist at the fetal/placental barrier; however their transcriptional
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regulation and function are different. The two forms of 11β-HSD are 11β-HSD-1 and 11β-HSD2. During development, 11β-HSD-2 is localized to the fetal placental barrier while 11β-HSD-1
has more broad reaching effects. The 11β-HSD-2 isoform has a two to five-fold higher affinity
for corticosterone but a very weak affinity for DEX. Similarly, 11β-HSD-1 has lowered affinity
for CORT and no measurable affinity for DEX. In essence, DEX circulating in the maternal
blood system is capable of passing through the fetal placental barrier almost unchecked (Yang,
1995).
Another regulatory component for the control of circulating corticosterone is
corticosterone binding globulin (CBG). Essentially, CBG binds circulating corticosterone and
sequesters it so that it becomes incapable of binding its MR and GR receptor targets. Although
CBG is a very powerful regulator of corticosterone action, it has been shown that chronic stress
and the consequent increase in corticosterone levels causes a decrease in circulating maternal
CBG. As a result of this down regulation of CBG in the maternal environment, the fetus is more
exposed to increases in corticosterone levels experienced by the mother (Takahashi, Turner, &
Kalin, 1998). It should be noted that CBG is similar to 11β-HSD-2 in that it has a very high
affinity for corticosterone and a very low affinity for DEX. Since DEX is not tightly regulated by
11β-HSD-1, 11β-HSD-2, or CBG especially during maternal stress, it easily passes from the
maternal environment to the fetal environment through the fetal placental barrier (Weisner, Do,
& Feldman, 1979).
As mentioned previously, the down regulation of CORT occurs due the similarities
between DEX and CORT and the synthetic steroid’s capacity to reduce CORT synthesis and
release following DEX-induced negative feedback. When MR and GR in response to DEX or
CORT receptors are activated, they act on a number of systems, including the regulation of
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serotonin, 5HT. In fact, the balance between activation of glucocorticoid receptors and 5HT
receptors ultimately controls the HPA axis negative feedback system (Gold & Chrousos, 1999).
For example, when synthetic glucocorticoids are added, they inhibit endogenous CORT and
drive 5HT regulation.
Serotonin is a tryptophan derived neurotransmitter and its actions are associated with
numerous neurological regions (Jacobs & Azmitia, 1992). 5HT released from the presynaptic
neurons, binds a number of cell surface receptors and generates a wide variety of second
messengers (Barnes & Sharp, 1999). The activation of these receptors has been linked to many
cognitive behaviors including learning (Meneses, 1999). Specifically, in regards to memory, the
5HT1A receptor has been associated with the regulation of working memory (Dourish, Ahlenius,
& Hutson, 1987). The highest levels of 5HT1A receptors are found in the limbic regions of the
brain such as the hippocampus, raphe nuclei, amygdala, hypothalamus, and cortex. Of these the
hippocampus has been found to be very important in the processing of new memories (Kung,
Zhuang, Frederick, & Kung, 1994). Since this receptor is expressed very early during
development, it is a target for modulation by a number of prenatal effectors such as stress or
DEX exposure (del Olmo, Lopez-Gimenez, Vilaro, Mengod, Palacios, & Pazos, 1998).
The 5HT1A receptors in the hippocampus are tightly regulated by glucocorticoids as
shown by adrenalectomy. This loss of the adrenal gland essentially removes the glucocorticoid
release in response to ACTH and is associated with a greater number of 5HT1A receptors as well
as an increase in 5HT1A receptor mRNA transcripts. However, when a glucocorticoid such as
CORT or DEX was introduced into the system, the 5HT1A receptor density and mRNA
expression returned to that of control animals (Zhong & Ciaranello, 1995). This suggests that
CORT negatively regulates the gene regulation of 5HT1A receptors in adult animals.
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In this study the aim is to explore 5HT1A receptor function in the adult rat after changes
to HPA axis function have occurred during development. Prenatally stressed male rats show
HPA axis hyperactivity and an alteration in MR and GR density in adulthood (Kalinyak, Griffin,
Hamilton, Bradshaw, Perlman, & Hoffman, 1989) (Meaney, Sapolsky, & McEwn, 1985).
The vast majority of the 5HT receptors belong to a large class of signaling receptors
called G-protein coupled receptors (GPCRs). These GPCRs are seven membrane pass proteins
that have their N-terminus on the extracellular domain and the C-terminus on the cytoplasmic
side. This general structure is true for all 5HT receptors except 5HT3 (Pierce, Permont, &
Lefkowitz, 2002).
The binding of serotonin to the extracellular domain of the GPCR causes the receptor to
undergo a conformational change which then causes the intracellular G-protein to be activated.
Both the intracellular region and extracellular region have three looping regions. The current
model has the binding of the intracellular heterotrimeric G-protein occurring at the intracellular
loops 2 and 3, with intracellular loop 2 causing the activation of the G-protein (Horn, Van der
Wenden, Oliveiera, Ijzerman, & Vriend, 2001) (Bourne, 1997). The G-protein is a heterotrimeric
protein with an α, β, and γ subunit. The α subunit contains the GTP/GDP binding domain from
which the receptor and protein derive their name. The α subunit also contains a GTPase which
hydrolyzes the GTP to GDP to inactivate the protein, while the receptor acts as the GDP to GTP
exchange factor. Once the receptor has been activated and the GDP has been exchanged for GTP
on the α subunit, the α subunit goes on to activate a set of downstream targets, while the βγ
subunit dissociates from the heterotrimer and activates its own downstream targets (Clapman,
1996).
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The overall goal of this study is to evaluate potential changes in the density (Bmax),
affinity (Kd) of the 5H1A receptor. Thus, a radio- labeled binding assay was performed in order
to measure the density and affinity of receptors. In addition, the GTPγS incorporation assay was
conducted in order to measure potency, which reflects the effective concentration of agonist
required to stimulate the incorporation reaction to 50% maximum (EC50), and efficacy (Emax) or
effectiveness of the 5HT1A receptor transduction activity in the hippocampi of the prenatally
DEX treated rats..
The binding assay operates on the assumption that when the reaction is terminated by
filtration, the system has reached steady state equilibrium with the receptor (R), ligand (L) and
receptor ligand complex (LR) (Scheme 1). The steady state can be represented as:
Scheme 1: Steady state equation for binding assay
𝐿 + 𝑅 ⟺ 𝐿𝑅

The measure of affinity is determined by the receptor Kd. The Kd is the ratio of the association
constant (K1) and the dissociation constant (K2) (Scheme 2) (Zettner, 1973).
Scheme 2: Kinetics of Kd
𝐾1

𝐿 + 𝑅 �� 𝐿𝑅

𝐿𝑅 �� 𝐿 + 𝑅
𝐾2

𝐾2
= 𝐾𝑑
𝐾1

The Kd is also equal to the concentration of ligand required to occupy 50% of the total receptors
available for binding (Bmax)
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Figure 2. Representative binding curve showing Bmax and Kd.
An important assumption that is made in the calculations for Kd and Bmax is that when the
steady state of a system is reached, the concentration of ligand is unchanged. In order for this
assumption to be true, the concentration of ligand must be in large excess, relative to the receptor
concentration, during the course of the reaction. When this is true, we are allowed to make the
assumption that (Zettner, 1973):
[𝐿]𝑡𝑜𝑡𝑎𝑙 = [𝐿]𝑓𝑟𝑒𝑒 − [𝐿𝑅]

This allows us to say that the concentration of free ligand [L]free is equal to the concentration of
ligand that was added originally, if and only if the concentration of receptor is negligible in
relation to the receptor concentration. When conducting binding studies, the ligand that is used is
very critical. Three major classes of ligands exist. The first class includes agonists. The function
of agonists is to bind the receptors in the active conformation and elicit the intended response.
The second class is antagonists. A pure antagonist does not only bind the receptors in the active
conformation but also binds the receptors in the inactive conformation. By binding both
conformations of the receptor, antagonists give a better representation of the total receptor count.
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The third class of ligand is the inverse agonist. This class of receptors also binds both the active
and inactive conformations of the receptor, but also causes the receptor activity to be driven in
reverse. In this experiment, the antagonist 2'-methoxyphenyl-(N-2'-pyridinyl)-p-fluorobenzamidoethyipiperazine (MPPF) was used as it is highly selective for the receptor of interest,
the 5HT1A receptor (Foster, et al., 1995). A tritium tag was added to the MPPF so its presence
could be detected through the use of liquid scintillation.
One common problem that arises in the use of binding assays is non-specific binding.
Non-specific binding occurs when the ligand, in this case [H3 MPPF], binds to another receptor
in its family or to other constituents of the tissue. To block against non-specific binding, a nonlabeled ligand with a higher affinity for the 5HT1A binding site and at a concentration that is
large enough to block all specific binding sites within the sample is incubated with the labeled
ligand. This then forces the labeled ligand to bind to non-specific sites. This can then be
accounted for in the analysis so only specific binding sites are counted (Zettner, 1973). In this
experiment, WAY100635 was used as the non-specific antagonist (Foster, et al., 1995).
To analyze the EC50 and Emax of the 5HT1A receptors in the hippocampus, a GTPγS35
assay was used. The GTPγS35 incorporation assay allows measurement of absolute levels of
GTPγS35 incorporation into the alpha-subunit following activation of a single receptor, in this
case, the 5HT1A. This assay unlike the binding assay relies on the irreversible incorporation of
the non-hydrolysable GTP analog GTPγS (Scheme 3, 4) (Odagaki & Fuxe, 1995a).
Scheme 3: Reactions representing the interactions between G-proteins and GTP
𝐵𝑖𝑛𝑑𝑖𝑛𝑔

(𝐺𝑝𝑟𝑜𝑡𝑒𝑖𝑛 − 𝐺𝐷𝑃𝑏𝑜𝑢𝑛𝑑 ) + 𝐺𝑇𝑃𝑓𝑟𝑒𝑒 �⎯⎯⎯⎯� (𝐺𝑝𝑟𝑜𝑡𝑒𝑖𝑛 − 𝐺𝑇𝑃𝑏𝑜𝑢𝑛𝑑 ) + 𝐺𝐷𝑃𝑓𝑟𝑒𝑒

𝐻𝑦𝑑𝑟𝑜𝑙𝑦𝑧𝑎𝑡𝑖𝑜𝑛

𝑅𝑒𝑠𝑒𝑡

�⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯� (𝐺𝑝𝑟𝑜𝑡𝑒𝑖𝑛 − 𝐺𝐷𝑃𝑏𝑜𝑢𝑛𝑑 ) + 𝑃𝑖𝑓𝑟𝑒𝑒 �⎯⎯� (𝐺𝑝𝑟𝑜𝑡𝑒𝑖𝑛 − 𝐺𝐷𝑃𝑏𝑜𝑢𝑛𝑑 ) + 𝐺𝑇𝑃𝑓𝑟𝑒𝑒
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Scheme 4: Reaction representing the interaction between G-proteins and GTPγS
𝑏𝑖𝑛𝑑𝑖𝑛𝑔

35
35
𝐺𝑝𝑟𝑜𝑡𝑒𝑖𝑛 + GTPγS𝑓𝑟𝑒𝑒
�⎯⎯⎯⎯� 𝐺𝑝𝑟𝑜𝑡𝑒𝑖𝑛 − GTPγ𝑆𝑏𝑜𝑢𝑛𝑑

In the reaction with GTPγS35, the molecule is non-hydrolysable due to the gamma phosphate
having a sulfur atom in place of oxygen. The sulfur atom is both larger and less electronegative.
This renders it a poor electron acceptor during the hydrolysis process (Harrison & Traynor,
2003).
Since the binding of the GTPγS35 is irreversible, it makes sense that the assay is based on
absolute binding, not equilibrium. As a result, this assay is highly time sensitive. The
incorporation of the GTPγS35 is linear therefore the total time the reaction proceeds is not
critical, it is only critical that all experiments utilize the same amount of time (Alper & Nelson,
1998).
In order to stimulate the 5HT1A receptor to bind the GTPγS35 the 5HT1A selective
receptor agonist ±7-(Dipropylamino)-5, 6, 7, 8-tetrahydronaphthalen-1-ol (8-OH-DPAT) was
used (Alper & Nelson, 1998). Since 8-OH-DPAT is a receptor agonist, it will only bind only
receptors that are in the active conformation.
Like the binding assay, the GTPγS35 binding assay is also prone to non-specific binding.
To account for this, an excess of unlabeled GTPγS is added to the reaction and binds all of the Gprotein binding sites. This forces the radioactively labeled GTPγS35 to bind only non-specific
sites. This can then be subtracted out the same way it is in the binding assay (Alper & Nelson,
1998).
The Emax is the maximum response that can be elicited from a receptor population and it
is a measure of the drug (agonist) efficacy, while the EC50 is the concentration that is halfway
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between the maximum and minimum activation during the specified time course of the
experiment (Figure 2) (Sjogren, Csoregh, & Sven ningsson, 2008).

Emax

Midpoint

Minimum Stim

EC50

Figure 3. Representative GTPγS35 incorporation curve showing Emax and EC50.
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Specific Aims of Study
Using these techniques, the goal of this investigation was to analyze the effects of a
prenatal exposure to Dexamethasone on the 5HT1A receptor number and activity. In addition,
the effect of acute stress on receptor function was also examined. As Dexamethasone is used
clinically to stimulate lung development, it is important that the long term effects of this drug are
analyzed (Kattner, Metze, & Waisse, 1992) (NIH Consensus, 2000). Previous studies have
shown that a prenatal exposure to DEX increases hippocampal drive and HPA axis activity
which affects normal corticosterone rhythms. It is very likely that the disturbance is causing
problems in neurophysiology as the HPA axis and receptor development are closely related
(Shoener, Baig, & Page, 2005). Although the circulating glucocorticoids levels are closely
controlled by regulatory proteins in the maternal fetal-placental barrier, DEX seems to be
unaffected by these protective regulatory proteins due to low binding affinity (Weisner, Do, &
Feldman, 1979). This results in a glucocorticoid excess in the form of DEX in the fetal
environment, which alters the hippocampal MR/GR balance, and disturbs the set point for
negative feedback regulation of CORT after birth. The excess DEX also attenuates maternal
corticosterone which regulates the developing serotonergic system and influences serotonin and
5HT1A receptor relationships that are established in utero (Dallman, et al., 1992) (Ratka,
Sutanto, Bloemers, & de Kloet, 1989) (Zhong & Ciaranello, 1995).
Acute stressors applied postnatally have been shown to cause improvement in memory
consolidation (Oitzl & de Kloet, 1992). Unlike chronic stress which is associated with major
gene transcription, acute stress in the postnatal environment is more likely to engage immediate
receptor responses associated with 2nd messenger signaling.
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Our aim was to determine whether prenatal Dexamethasone treatment elicits alterations
in 5HT1A receptor density, extracellular binding affinity, potency of signal transduction, and
intracellular incorporation of GTPγS35 into the alpha subunit of an activated G-protein. In
addition we investigated these properties of the 5HT1A receptor following acute stress.
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Materials and Methods
Materials
Tris(hydroxymethyl)aminomethane

(Sigma-Aldrich,

St

Louis,

MO),

Guanosine

triphosphateγS35 (Perkin Elmer, San Jose, CA), Guanosine diphosphate (Perkin Elmer, San Jose,
CA) Guanosine diphosphate (Sigma Aldrich, St. Louis MO), Way100635 (Sigma Aldrich, St
Louis MO), 2'-methoxyphenyl-(N-2'-pyridinyl)-p-fluoro-benzamidoethyipiperazine (MPPF3H)
(Perkin Elmer, San Jose, CA), EcoLume Scintillation Fluid (Beckman Coulter, Brea, CA),
polyethylenimine (Sigma-Aldrich, St. Louis, MO), Dexamethasone (Dex) (Sigma-Aldrich, St
Louis, MO), Guanosine triphosphate gamma sulfate (Sigma-Aldrich, St. Louis, MO), 7(Dipropylamino)-5,6,7,8-tetrahydronaphthalen-1-ol (8-OH-DPAT) (Sigma-Aldrich, St Louis
MO)
Animal Treatment
Time mated Sprague-Dawley Dams (n=17, DEX=9, Control=8) were obtained (Hilltop
Laboratories) on gestation day 7. After transport, the rats were given one week of acclimation
before DEX treatment was started. During the third week of gestation, dams were randomly
assigned to receive daily sub cutaneous injections of DEX (150 µg · kg-1 · day-1; n= 8) or vehicle
(saline + 0.4% ethanol, n=9) during days 14-19 of gestation. Day 0 is defined as the morning of
appearance of the vaginal plug and rat gestation lasts 21-22 days. All animals were maintained
under 12 hour light (0600 to 1800) and constant temperature of 23°C. Water and food were
provided ad libitum. Male offspring were weaned on postnatal day 21 and housed 2 per group
according to litter and treatment. Non-stressed animals were euthanized following brief exposure
to CO2 in a pre-charged chamber and rapid decapitation by guillotine one week after behavior
testing. Stressed animals were euthanized one and a half hours after a second exposure to the
elevated plus maze to induce a postnatal stressor. This was done one week after initial behavior
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testing was complete. Following decapitation trunk blood was collected and both hippocampi
were extracted and frozen at -80°C and trunk blood was taken and stored at -80°C.
Tissue Preparation
Hippocampus samples were removed from -80°C freezer, weighed, and placed in 5mL of
50mM Tris pH 7.4 at 4°C. Samples were homogenized using a chilled polytron probe for 10
seconds in polypropylene oak ridge tubes. Residual sample from probe was recovered with a 3
second recovery in fresh 5mL of 50 mM Tris pH 7.4 at 4°C. Samples were mixed and spun for
20 minutes at 18,000 rpm in a Beckman J2000 centrifuge using the JA-20 rotor. Homogenization
and centrifugation were then repeated with fresh 5mL of 50 mM Tris pH 7.4 at 4°C. Final
homogenization was performed with room temperature (RT) 20 mM Tris pH 7.4.
Binding Assay
After final homogenization 20 mM Tris pH 7.4 at RT was added in sufficient volume to
bring tissue concentration to 4 mg/ml. A 2 fold serial dilution for 2.64 nM MPPF3H was
conducted such that the most dilute concentration of MPPF3H was 0.0413 nM. Each assay
contained, 500 µL of tissue, 250 µL of 20 mM Tris pH 7.4 at RT, and 250 µL MPPF3H. Total
activity tubes received 250 µL of appropriate MPPF3H dilution. Non-specific binding was
achieved using 2 µM Way 100635. For non-specific tubes, 250 µL of Way 100635 replaced the
250 µL of 20 mM Tris pH 7.4 at RT. Way 100635 was diluted to 2 µM using 20 mM Tris pH 7.4
at RT. Reaction was incubated for 1 hour in a 25 °C water bath. Reaction was stopped by rapid
filtration using a Brandel Cell Harvester (Brandel, Gaithersburg, MD). A Whatman FP-100
glass filter membrane was used (Brandel, Gaithersburg, MD). Membrane was soaked in a
polyethylenimine solution for 1 hour prior to harvesting. Filters were washed 3 times with 20
mM Tris pH 7.4 at 4°C. Filters were then dried at room temperature for one hour and retained
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radioactivity was counted using a Perkin Elmer Tri-Carb (Perkin Elmer, San Jose, CA).
Scintillation vials were filled with 3 mL of scintillation fluid. Data was analyzed Graphpad
software using a specific + non-specific non-linear global fit. Group sizes were control nonstressed (n=9), control stressed (n=18), DEX non-stressed (n=9), and DEX stressed (n=18).
GTPγS Incorporation Assay
Tissue frozen at -80°C from binding assay with concentration 4 mg/mL was further
diluted to 1 mg/mL using 50 mM Tris pH 7.4 at RT after being thawed on ice. For non-specific
binding 500µL of tissue was combined with 250µL of 43µM GTPγS and 250µL of 100pM
GTPγS35. Remainder of assay tubes contained 500µL of tissue, 250µL of 8-OH-DPAT
(concentrations ranging from 1.25E-5M to 6.35E-10M), and 250µL 100pm GTPγS35. Basal
activity was measured by substituting 50mM Tris pH 7.4 at RT for the drug. Assay was carried
out in triplicates and was incubated for exactly 45 minutes in a 27°C water bath. Reaction was
stopped by rapid filtration using a Brandel Cell Harvester (Brandel, Gaithersburg, MD). A
Whartman FP-100 glass filter membrane was used (Brandel, Gaithersburg, MD). Filters were
washed 3 times with 20 mM Tris pH 7.4 at 4°C. Filters were then dried at RT for one hour and
retained radioactivity was counted using a Perkin Elmer Tri-Carb (Perkin Elmer, San Jose, CA).
Scintillation vials were filled with 3 mL of scintillation fluid. Data was analyzed Graphpad
software using a 3-parameter curve fit. Group sizes for incorporation data were control nonstressed (n=9), control stressed (n=9), DEX non-stressed (n=8) and DEX stressed (n=9)
Statistical Analysis
Analysis of variance (ANOVA) for non-repeated measures was used to analyze all
variables (Kd, Bmax, EC50, and Emax). Post hoc comparisons were conducted using the Bonferroni
analysis. Effects were considered statistically significant if p˂0.05.
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Results
Binding Assay
The 5HT1A receptor is an important receptor associated with learning and memory
(Dourish, Ahlenius, & Hutson, 1987). The receptor induces the activation of a heterotrimeric Gprotein that inhibits downstream signaling molecules (Pucadyil, Kalipatnapu, & Chattopadhyay,
2004). To study the receptor, a 5HT1A binding assay and GTPγS35 incorporation assay were
performed to analyze the receptors affinity (Kd), total receptor count (Bmax), potency (EC50), and
efficacy (Emax).
Changes in Kd in response to Prenatal DEX and Acute Stress
The Kd data from the binding experiment with the 5HT1A selective receptor antagonist
[3H] MPPF showed that the affinity at which the 5HT1A receptor bound its ligand decreased in
response to prenatal DEX under resting conditions. This resulted in a significantly higher Kd
value in the DEX non-stressed animals (DEX non-stressed: 0.71±0.02 nM, Control non-stressed:
0.58± 0.04 nM, p<0.05; figure 5).
In addition to the significant changes in Kd associated with prenatal DEX exposure,
postnatal acute stress also elicited significant changes in the receptor Kd. In response to stress the
Kd for the DEX treated animals significantly decreased in comparison to their non-stressed
cohorts (DEX non-stressed: 0.71±0.02 nM, DEX stressed: 0.561±0.019 nM, p<0.05, figure 5).
This change was not observed in control groups, as the Kd for the stressed group of control
animals decreased, but not by a significant amount (figure 5).
Overall a prenatal exposure to DEX caused a significant change in Kd as DEXtot (DEX
stressed+ DEX non-stressed) had a significantly higher Kd than Controltot (Control stressed+
control non stressed) (DEXtot: 0.61±0.02 nM, Controltot: 0.53±0.02 nM, p<0.05, figure 6). In
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contrast, the acute stressor caused a significant decrease in Kd for stressedtot (Control stressed+
DEX stressed) in comparison to the non-stressedtot animals (Control non-stressed+ DEX nonstressed) (stressedtot: 0.532±0.012 nM; non-stressedtot: 0.64± 0.03 nM, p<0.05, figure 6).
These results show that a prenatal treatment with DEX causes attenuation in receptor
affinity under non-stressed conditions, but when the receptor is in a stressed environment the
receptor Kd decreases for both groups. The order of receptor affinities from least to greatest is as
follows: DEX Non-stressed< DEX Stressed = Control Non-Stressed < Control stressed. If we
compare these results to the binding results listed in the following section, the trend indicates that
the population with the most receptors has the highest Kd while the population with the fewest
receptors has the lowest Kd.
Effects of Stress and Prenatal DEX on Bmax
As shown in figure 7 a prenatal exposure to DEX or an acute exposure to stress did not
cause a significant change in Bmax when comparing the two groups. However, when the entire
prenatal DEX population DEXtot, is compared to the entire control population, Controltot, there is
a significant increase in the Bmax of the prenatally DEX treated animals (DEXtot: 25.2±0.6
fmoles/mg, Controltot: 22.5±0.6 fmoles/mg, p<0.05, figure 8). Additionally, the stressedtot
animals had a significantly lower Bmax in comparison to the non-stressedtot group (stressedtot:
23.2±0.6 fmoles/mg, non-stressedtot: 25.2± 0.7 fmoles/mg, p<0.05, figure 8). These results tell us
that a prenatal exposure to DEX is associated with a significant increase in the density of 5HT1A
receptors, while an acute stressor induces a significant decrease in 5HT1A density (figure 7). The
ranking of receptor densities from least dense to most dense seems to be Control stressed<
Control Non-stressed< DEX stressed< DEX non-stressed.
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Incorporation Assay
Given the results of the binding assay which showed that a prenatal exposure affected
both the density and affinity of the 5HT1A receptor in the hippocampus, the next step was to
examine potential changes in the downstream signaling. To measure these values a GTPγS35
incorporation assay was used. This assay allows measurement of the receptors potency (EC50)
and the efficacy (Emax) (figure 9).
EC50 changes in response to stress and prenatal DEX
The results of the GTPγS35 incorporation assay showed that there were no statistically
significant changes in the E50 for any of the groups regardless of treatment (figure 10 and 11).
Emax changes in response to stress and prenatal DEX
Although there was no change in the EC50 for the 5HT1A receptor in any of the
conditions, the Emax indicates that the changes in receptor Kd and Bmax in response toacute stress
influence G-protein signaling linked to the 5HT1A receptor. In response to stress both the
control and the DEX treated animals exhibited a significant increase in their respective Emax
(Control Non-stressed: 7.0±0.4 fmoles/mg, Control Stressed: 9.8±0.5 fmoles/mg, p<0.05, figure
12) (DEX Non-Stressed: 7.7± 1.1 fmoles/mg, DEX Stressed: 11.2±0.3 fmoles/mg, p<0.05, figure
12). Further analysis of the stressed data shows that the stressedtot group had a significantly
higher Emax in comparison to the Non-stressedtot group (Stressedtot: 10.5±0.3 fmoles/mg, Nonstressedtot: 7.3±0.6 fmoles/mg, p<0.05, figure 13).
In contrast, a prenatal exposure to Dexamethasone was not associated with significant
changes in Emax when comparing non-stressed or stressed animals. This data shows that stress
has a greater impact on the 5HT1A receptor efficacy compared to the effects of a prenatal
exposure to DEX.
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Discussion
In our study we were able to show that a prenatal exposure to DEX as well as a postnatal
exposure to acute stress in adulthood results in a significant alteration in the 5HT1A receptor Kd.
More specifically it was found that prenatal DEX exposure was associated with a significant
increase in the Kd of the 5HT1A receptor, which indicates a reduction in receptor affinity for its
ligands. In contrast, the opposite trend in receptor affinity was observed in both DEX and control
animals in response to stress. The effects of an acute stressor applied 1.5 hours prior to sacrifice
reduced the 5HT1A receptor Kd in both DEX and control hippocampi which suggests that
receptor affinity was increased (figure 5, 6).
It could be said that the effect of stress on Kd was not unexpected since it is known that
learning is enhanced when the task being learned is coupled to a stressful event. Ultimately,
stressors such as injected glucocorticoids or environmental stress are linked to increases in
plasma CORT (Sandi, Loscertales, & Guaza, 1997), but the physiological link between high
CORT levels and increases in 5HT1A receptor affinity remains unclear.
One plausible explanation that is gaining popularity is the idea that there are changes in
lipid raft composition in association with membrane cholesterol in regions where 5HT1A
receptors are located. It has been shown that increases or decreases in membrane cholesterol
concentrations can have a direct impact on the affinity of the 5HT1A receptors. For example,
increases in cholesterol are associated with an increase in receptor affinity, while sequestering
cholesterol has the opposite effect (Pucadyil & Chattopadyay, 2004). It is also known that
cholesterol in the membrane is not randomly distributed, but rather localized into raft regions
that contain special lipids such as sphingolipids and phosphoglycerolipids. These are different
than the typical glycolipids found on the other parts of the plasma membrane because these have
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completely saturated acyl chains. This allows for greater hydrogen bonding and aggregation of
these special lipids. In these domains cholesterol is found with sphingolipids and
phosphoglycerolipids in a 1:1:1 ratio (Edidin, 2003). Although the link between acute stress and
cholesterol distribution in the membrane has not been studied extensively, data has shown that
increases in corticosterone are coupled to increases in plasma cholesterol (Barker, 1995).
Whether plasma cholesterol is incorporated into the membrane is doubtful as it has also been
shown that all cholesterol in the brain is produced locally (Jurevics & Morell, 1995). However
the relationship between corticosterone production and potential elevations in brain cholesterol
levels could provide insight into the increased receptor affinity associated with acute stress found
in our study. The idea of cholesterol contributing to 5HT1A receptor function has been reported
in the literature and is further supported by the fact that 5HT1A receptors are GCPRs that require
cholesterol for proper function (Pucadyil & Chattopadyay, 2004) (Pierce, Permont, & Lefkowitz,
2002).
In contrast to the stress induced increase in 5HT1A affinity, prenatal DEX-exposure was
associated with a significant attenuation in receptor affinity (figure 5, 6). However, the proposed
cholesterol explanation could also be used to support this latter finding as follows: Prenatal
exposure to DEX has been shown to reduce maternal circulating CORT, and yet, it increases
plasma glucocorticoids since the administered DEX is a glucocorticoid. The high levels of
circulating DEX induce negative feedback by interacting with GR receptors, the primary
receptor involved in CORT feedback, which lowers the maternal and fetal corticosterone levels
following DEX administration during the third trimester (Nyirenda, Welberg, & Sekel, 2001)
(Rupprecht, Reul, & Van Steensel, 1993). It is highly possible that if membrane cholesterol is
driven by circulating CORT, and these levels are reduced in DEX-treated animals, then the
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lowering of maternal and fetal CORT levels could be coupled to cholesterol reduction.
Particularly neuronal cholesterol since its level is set late in gestation (Turley, Bruns, &
Dietschy, 1998). This putative disturbance in the set-point of neuronal cholesterol could be
associated with the increased Kd and decreased affinity observed for 5HT1A receptors in the
DEX-exposed non-stressed animals (Figure 5). As mentioned, neuronal cholesterol levels are
determined late in gestation, during what is clinically known as the third trimester. Since reduced
circulating prenatal and maternal cerebral corticosterone have been observed during this time, it
is possible that this change is involved in the altered cholesterol set point in the developing DEXtreated fetus (Nyirenda, Welberg, & Sekel, 2001) (Takahashi L. K., 1998) (Turley, Bruns, &
Dietschy, 1998).
In addition to the changes in receptor affinity we also observed significant changes in
5HT1A receptor density (Bmax) when comparing the total populations of prenatally DEX treated
animals (DEXtot) to the total control population (Controltot) and between the total stressed group
(stressedtot) and the total non-stressed group (non-stressedtot) (figure 8). The significant up
regulation in Bmax detected in DEX-treated animals is supported from previous studies that
measured the concentration of 5HT1A receptor post gestation in the prefrontal cortex. However,
in that particular study there was no significant decrease in 5HT levels or turnover coupled to the
increase in the 5HT1A receptor density (Slotkin, Kreider, Tate, & Seidler, 2006). This suggests
that there is a change in the postsynaptic transmission. It is possible that the up-regulation of
5HT1A receptor is a compensatory response due to the lack of downstream signaling (Shahak &
Slotkin, 2003) (Slotkin, Kreider, Tate, & Seidler, 2006). Our model fits this hypothesis since we
found a decrease in receptor affinity in prenatally DEX-treated animals which is coupled to a
significant increase in 5HT1A receptor density (figure 6, 8). Thus the decrease in ligand
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effectiveness and reduction in downstream activation would trigger up regulation of the receptor
number in order to compensate for the loss in efficacy.
A second possible explanation for the increase in 5HT1A receptor expression can be
constructed from the changes in HPA axis programming which occurs during the time of DEX
administration. DEX-exposure during the third trimester elicits a number of regulatory issues for
the developing neuroendocrine system (Shoener, Baig, & Page, 2005). (1) DEX administration
causes a significant decrease in the circulating levels of maternal and thus fetal CORT, (2) DEX
preferentially binds to GR receptors that under basal CORT conditions would not be activated
due to MR’s higher affinity for DEX (Nyirenda, Welberg, & Sekel, 2001) (Rupprecht, Reul, &
Van Steensel, 1993). This preferential binding of GR receptors by DEX alters the negativefeedback regulation of 5HT1A expression that is typically mediated by MR under basal
conditions (Meijer & De Kloet, 1994) (Kuroda, Watanabe, Alkbeck, Hastings, & McEwen,
1994). Therefore, if the MR negative feedback regulation is less effective during the time of
neuroendocrine set point determination, the fetal brain could be set to have a less effective
regulation of 5HT1A receptors during adulthood. As regulatory influence is decreased, an
elevation in 5HT1A receptor number may result. This is what was observed in our experiment
(figure 8).
Not only did a prenatal exposure to DEX cause a significant increase in the density of the
5HT1A receptor, but an acute stressor administered 1.5 hours prior to sacrifice significantly
decreased the 5HT1A receptor density. Previous studies have shown that CORT exerts a direct
negative regulation of 5HT1A receptors by acting through its MR receptors. Activated MR then
acts to inhibit 5HT1A mRNA and induces degradation or internalization of existing 5HT1A
receptors (Meijer & De Kloet, 1994) (Kuroda, Watanabe, Alkbeck, Hastings, & McEwen, 1994).
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Since CORT levels are significantly increased in response to stress it is likely that its effect on
MR activation would serve to reduce receptor density and lower Bmax as was observed in our
experiment (Barker, 1995) (figure 8). In addition, studies have shown that hippocampal 5HT1A
receptors can begin to change in response to adrenalectamy in as little as one hour (Zhong &
Ciaranello, 1995). From this it is reasonable to assume that within 1.5 hours, enough time has
passed for changes to have occurred which lead to a decrease in 5HT1A receptors in response to
elevated CORT .
In our study, the increase in receptor affinity that is associated with acute stress seems to
be coupled to an increase in Emax as the stressed groups of Control and DEX all showed a higher
Emax figure 12, 13). Studies have shown that acute stress is associated with an increase in
memory consolidation and that this process may result from an increased 5HT1A activation in
response to stress since the 5HT1A receptor is associated with new memory formation (Douglas,
1975) (Ohno & Watanabe, 1996) (Oitzl & de Kloet, 1992). In our study, 5HT1A receptor
potency, EC50, did not change but a significant decrease in the total number of 5HT1A receptor
was detected in response to stress. This would possibly lead one to think that the changes in
receptor activation were due to the increased affinity during stress. However, when the Emax is
measured, the effect of affinity is made negligible by increasing the concentrations to a
saturation point for the receptor system. One possible explanation then for the change in receptor
activation in response to stress could again be the increased membrane cholesterol that is being
hypothesized. Since receptors are present in both the active and inactive conformation, it is
possible that due to increased membrane cholesterol and therefore increased concentrations of
lipid rafts, a greater number of receptors are present in the active conformation. By having a
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population shift toward more receptors in the active conformation, the cell is then capable of
activating more G-proteins in response to ligand binding.
The cholesterol hypothesis further supports the stress mediated increase in Emax because
lipid raft formation is crucial for the proper activation of the GPCR class of receptors which
includes the 5HT1A receptor (Pierce, Permont, & Lefkowitz, 2002). Therefore as a result of an
increase in circulating corticosterone, the corresponding increase in membrane cholesterol allows
for higher affinity of the 5HT1A receptor for its ligand, which is possibly associated with a
population shift toward more receptors in the active conformation, which leads to increased
levels of downstream signaling in response to a postnatal stressor.
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Conclusions and Future Directions
From the results of this study we are able to conclude that a prenatal exposure to
Dexamethasone causes a significant decrease in 5HT1A receptor affinity under resting
conditions. The change in receptor affinity then seemed to elicit an increase in the receptor Bmax
as a means of compensation to restore “normal” amounts of downstream signaling as was
indicated by the Emax which showed that prenatally DEX treated animals showed no significant
change in downstream signaling in response to the alterations to Kd and Bmax.
However, under stressed conditions the DEX and control groups indicated that elevated
levels of CORT can be correlated to an improved Kd, a lowered Bmax, and also an increased Emax.
If the changes in receptor affinity are linked to membrane cholesterol, which has been shown to
increase in the plasma in response to circulating CORT, it is possible that the increase in Emax
during an acute stress response could be due to the increases in CORT (Barker, 1995). The
decreases in Bmax, though they do not seem to alter the effect of stress on Emax could also be
related to CORT increases during stress, as CORT has been shown to cause a decrease in 5HT1A
receptor expression (Zhong & Ciaranello, 1995).
From the results of this experiment, the next area of investigation would logically be to
test the effects of stress on membrane cholesterol and lipid raft composition as this may be the
missing link between our results and what is currently in the literature.
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Figure 4. Representative Binding assay for control stressed (n=18), control non-stressed (n=9),
DEX stressed (n=18), and DEX non-stressed (n=9) adult male rats. ( ) indicates curve for DEX
treated animals (non-stressed or stressed), ( ) represents control (non-stressed or stressed)
animals, ( ) represents control non-specific, and (x) represents DEX non-specific binding.
Specific binding was performed using dilutions of [3H] MPPF, a 5HT1A receptor antagonist
(ligand dilutions used: 0.0413, 0.0825, 0.165, 0.33, 0.66, 1.32, and 2.64). Non-specific binding
was carried out using Way100635 at a concentration of 2 µM. Left hippocampus was used for all
samples.
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Figure 5. The Kd for 5HT1A receptors using [3H] MPPF, a 5HT1A receptor antagonist, in the
left hippocampus of adult control stressed (n=18), control non-stressed (n=9), DEX stressed
(n=18), and DEX non-stressed (n=9) adult male rats. DEX non-stressed rats showed a significant
increase in Kd (decrease in affinity) in comparison to Control non-stressed and DEX stressed
groups (DEX non-stressed: 0.71±0.02 nM, Control non-stressed: 0.58± 0.04 nM, DEX stressed:
0.561±0.019 nM , p<0.05). Specific binding was performed using dilutions of [3H] MPPF, a
5HT1A receptor antagonist (ligand dilutions used were: 0.0413, 0.0825, 0.165, 0.33, 0.66, 1.32,
and 2.64 nM nM). Non-specific binding was carried out using Way 100635 at a concentration of
2µM. Left hippocampus was used.
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Figure 6. The Kd values for 5HT1A receptor binding using antagonist [H3] MPPF in the left
hippocampus of adult male rats. Results were grouped by treatment, Controltot (n=27), DEXtot
(n=27), non-stressedtot (n=18), and stressedtot (n=18). There was a significant increase in Kd in
prenatally DEX treated animals in comparison to control animals (DEXtot: 0.61±0.02 nM,
Controltot: 0.53±0.02 nM, p<0.05). In addition, stressedtot animals had a significantly lower Kd
compared to the non-stressed tot animals (Non-stressedtot: 0.64±0.03 nM, stressedtot: 0.523±0.012,
p<0.05). Binding was performed using dilutions of [3H] MPPF and Way100635 (specific and
nonspecific, respectively), as shown in Figure 5.
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Figure 7. Maximum binding (Bmax) of 5HT1A receptors in the left hippocampus in control nonstressed (n=9), control stressed (n=18), DEX non-stressed (n=9), and DEX stressed (n=18) adult
male rats using a specific 5HT1A receptor antagonist [3H] MPPF. No significant changes were
detected in response to prenatal DEX or an acute stressor. Binding was performed using dilutions
of [3H] MPPF and Way100635 (specific and nonspecific, respectively), as shown in Figure 5.
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Figure 8. Binding Maximum (Bmax) for left hippocampus from drug treated (Controltot (n=27),
DEXtot (n=27)) and stress challenged (non-stressedtot (n=18), and stressedtot (n=18)) animals. To
measure 5HT1A binding, a selective receptor antagonist [H3]MPPF was used. The DEXtot group
had a significantly higher Bmax in comparison to the Controltot group (DEXtot: 25.2±0.6
fmoles/mg, Controltot: 22.5±0.6 fmoles/mg, p<0.05). A significant result was also found in the
comparison between non-stressedtot and stressedtot groups (stressedtot: 23.2±0.6 fmoles/mg, nonstressedtot: 25.2± 0.7 fmoles/mg, p<0.05). Binding was performed using dilutions of [3H] MPPF
and Way100635 (specific and nonspecific, respectively), as shown in Figure 5.
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Figure 9. Representative GTPγS35 incorporation assay for DEX treated animals compared to
control animals. ( ) indicates curve for DEX (stressed) treated animals and ( ) represents
control (stressed) animals. 5HT1A receptors were activated using 8-OH-DPAT, a 5HT1A
specific agonist. Agonist concentrations used were: 1.25E-5, 4.175E-6, 1.39E-6, 4.625E-7,
1.543E-7, 5.15E-8, 1.715E-8, 5.725E-9, 1.905E-9, and 6.35E-9 M. The Log [DPAT]
concentration was plotted on the x-axis. Non-specific binding was measured using 43 µM
unlabeled GTPγS. Left hippocampus was used. Activity of receptor was recorded using 100pM
GTPγS35.
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Figure 10. EC50 values for control non-stressed (n=9), control stressed (n=9), DEX non-stressed
(n=8), and DEX stressed (n=9) adult male rats. Left hippocampus was tested using GTPγS35 as a
marker to measure activation of the 5HT1A receptors by 8-OH-DPAT, a 5HT1A agonist. There
were no significant changes in any of the treatment groups. Binding was performed as described
in figure 9.
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Figure 11. EC50 values for controltot (n=18), DEXtot (n=17), non-stressedtot (n=17), and stressedtot
(n=18) adult male rats. Left hippocampus was tested using GTPγS35 as a marker to measure
activation of the 5HT1A receptors by 8-OH-DPAT, a 5HT1A agonist. There were no significant
changes in any of the treatment groups. Binding was performed as described in figure 9.
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Figure 12. Emax values for control stressed (n=9), control non-stressed (n=9), DEX stressed (9),
and DEX non-stressed (n=8) adult male rats. Left hippocampus was tested using GTPγS35 as a
marker to measure activation of the 5HT1A receptors by 8-OH-DPAT, a 5HT1A agonist. A
significant increase in the Emax for the Control stressed and DEX stressed animals in comparison
to their respective non-stressed group (Control non-stressed: 7.0±0.4 fmoles/mg, Control
stressed: 9.8±0.5 fmoles/mg, DEX non-stressed: 7.7± 1.2 fmoles/mg, DEX stressed: 11.2±0.3
fmoles/mg, p<0.05). Binding was performed as described in figure 9.
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Figure 13. Emax values for controltot (n=18), DEXtot (n=17), non-stressedtot (n=17), and stressedtot
(n=18) adult male rats. Left hippocampus was tested using GTPγS35 as a marker to measure
activation of the 5HT1A receptors by 8-OH-DPAT, a 5HT1A agonist. The Emax for the stressed
group was significantly higher compared to the non-stressed group (stressedtot: 10.5±0.3
fmoles/mg; non-stressedtot: 7.3±0.6 fmoles/mg, p<0.05). No significant change was observed in
prenatally DEX treated animals compared to the control group. Binding was performed as
described in figure 9.
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Table 1. Summary of binding and incorporation results for control non-stressed, control stressed,
DEX non-stressed, and DEX stressed adult male rats (* indicates significance between control
vs. DEX within same stress paradigm, p<0.05. ˠ indicates significance between non-stressed vs
stressed within same drug treatment group, p<0.05.
Control NonStressed

DEX NonStressed

Control Stressed

Kd (nM)

0.58 ± 0.04

0.71 ± 0.02*

Bmax

23.6 ± 0.8

26.8 ± 0.9

21.9 ± 0.9

24.5 ± 0.8

0.133 ± 0.010

0.167 ± 0.010

0.162 ± 0.02

0.158 ± 0.02

7.0 ± 0.4

7.7 ± 1.3

0.5 ± 0.01ˠ

DEX Stressed
0.56 ± 0.02*ˠ

(fmol/mg)

EC50
(µM)

Emax
(fmol/mg)

9.8 ± 0.5ˠ

11.2 ± 0.3
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Table 2. Summary of binding and incorporation results for Controltot, DEXtot, non-stressedtot, and
stressedtot (* indicates significance between Controltot and DEXtot, p<0.05, ˠ indicates
significance between stressedtot and non-stressedtot, p<0.05).
Controltot

DEXtot

Non-Stressedtot

Stressedtot

Kd (nM)

0.53

±

0.02

0.61

± 0.02*

0.64

±

0.03

0.53

±

0.01ˠ

Bmax
(fmoles/mg)

22.5

±

0.6

25.2

±

0.6*

25.2

±

0.7

23.2

±

0.6ˠ

EC50 (µM)

0.147

± 0.013

0.162 ± 0.014

0.149

± 0.008

0.160

±

0.017

Emax
(fmoles/mg)

8.4

±

10.5

±

0.3ˠ

±

0.5

9.6

±

0.7

7.4

0.6

